CTNM Contineum Therapeutics, Inc.

Nasdaq www.contineum-tx.com


$ 11.93 $ -0.76 (-6.1 %)    

Friday, 17-Oct-2025 17:25:56 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 11.7
$ 12.42
$ 9.76 x 100
$ 13.89 x 2
$ 11.21 - $ 12.49
$ 3.35 - $ 20.24
102,704
na
328.09M
$ 0.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-16-2024 03-31-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 this-lululemon-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 this-biogen-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Core News & Articles

Leerink Partners analyst Faisal Khurshid initiates coverage on Contineum Therapeutics (NASDAQ: CTNM) with a Outperform ratin...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and raises the price ta...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

Core News & Articles

Contineum Therapeutics, Inc.

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and lowers the price ta...

Core News & Articles

RBC Capital analyst Brian Abrahams reiterates Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and maintains $31 price...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

Core News & Articles

Jones Trading analyst Debanjana Chatterjee initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Buy rating and ...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung assumes Contineum Therapeutics (NASDAQ:CTNM) with a Overweight rating and maintains Pric...

Core News & Articles

Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from ...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate...

Core News & Articles

- Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity- Topline data readout planned for ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION